299 related articles for article (PubMed ID: 22335060)
1. [Management of adverse effects of targeted therapy toxicities in oncology].
Coquan E; Henri P; de Raucourt S; Lireux B; Lamy E; Delcambre C; Sevin E; Dutriaux C; Bouhier-Leporrier K; Gervais R; Joly F
Rev Prat; 2012 Jan; 62(1):17-25. PubMed ID: 22335060
[TBL] [Abstract][Full Text] [Related]
2. Metabolic disorders associated with the use of targeted cancer therapies.
Kotecki N; Penel N; Awada A
Curr Opin Oncol; 2015 May; 27(3):258-66. PubMed ID: 25730544
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics.
Hammond-Thelin LA
Dermatol Clin; 2008 Jan; 26(1):121-59, ix. PubMed ID: 18023775
[TBL] [Abstract][Full Text] [Related]
4. Prevention and management of major side effects of targeted agents in breast cancer.
Metzger Filho O; Saini KS; Azim HA; Awada A;
Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e79-85. PubMed ID: 20817545
[TBL] [Abstract][Full Text] [Related]
5. Dermatologic toxicities of targeted anticancer therapies.
Balagula Y; Lacouture ME; Cotliar JA
J Support Oncol; 2010; 8(4):149-61. PubMed ID: 20822032
[TBL] [Abstract][Full Text] [Related]
6. Advances in the management of cutaneous toxicities of targeted therapies.
Robert C; Sibaud V; Mateus C; Cherpelis BS
Semin Oncol; 2012 Apr; 39(2):227-40. PubMed ID: 22484194
[TBL] [Abstract][Full Text] [Related]
7. [Managing cutaneous toxicities of targeted therapies].
Kiyohara Y
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1597-602. PubMed ID: 23152009
[TBL] [Abstract][Full Text] [Related]
8. Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices.
Appleby L; Morrissey S; Bellmunt J; Rosenberg J
Hematol Oncol Clin North Am; 2011 Aug; 25(4):893-915. PubMed ID: 21763973
[TBL] [Abstract][Full Text] [Related]
9. Dermatological side effects of current and upcoming targeted therapies in oncology.
Bonny M; Buyse V; Brochez L
Acta Clin Belg; 2011; 66(2):97-103. PubMed ID: 21630605
[TBL] [Abstract][Full Text] [Related]
10. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use.
Kirkali Z
BJU Int; 2011 Jun; 107(11):1722-32. PubMed ID: 21251188
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapies: a new generation of cancer treatments.
Gerber DE
Am Fam Physician; 2008 Feb; 77(3):311-9. PubMed ID: 18297955
[TBL] [Abstract][Full Text] [Related]
12. What kind of rash is it?: deciphering the dermatologic toxicities of biologic and targeted therapies.
Esper P; Gale D; Muehlbauer P
Clin J Oncol Nurs; 2007 Oct; 11(5):659-66. PubMed ID: 17962174
[TBL] [Abstract][Full Text] [Related]
13. Adverse events of targeted therapies.
Klastersky JA
Curr Opin Oncol; 2014 Jul; 26(4):395-402. PubMed ID: 24825019
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
Wood LS; Manchen B
Clin J Oncol Nurs; 2007 Oct; 11(5):649-56. PubMed ID: 17962173
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents.
Borovicka JH; Calahan C; Gandhi M; Abraham TS; Kwasny MJ; Haley AC; West DP; Lacouture ME
Arch Dermatol; 2011 Dec; 147(12):1403-9. PubMed ID: 22184762
[TBL] [Abstract][Full Text] [Related]
16. Molecular targeted therapies for solid tumors: management of side effects.
Grünwald V; Soltau J; Ivanyi P; Rentschler J; Reuter C; Drevs J
Onkologie; 2009 Mar; 32(3):129-38. PubMed ID: 19295254
[TBL] [Abstract][Full Text] [Related]
17. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic.
Rosen AC; Case EC; Dusza SW; Balagula Y; Gordon J; West DP; Lacouture ME
Am J Clin Dermatol; 2013 Aug; 14(4):327-33. PubMed ID: 23625802
[TBL] [Abstract][Full Text] [Related]
18. Side effects of targeted therapies: rash.
Eaby-Sandy B; Lynch K
Semin Oncol Nurs; 2014 Aug; 30(3):147-54. PubMed ID: 25085026
[TBL] [Abstract][Full Text] [Related]
19. Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management.
Liu S; Kurzrock R
Semin Oncol; 2015 Dec; 42(6):863-75. PubMed ID: 26615131
[TBL] [Abstract][Full Text] [Related]
20. Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer.
Tang N; Ratner D
Dermatol Surg; 2016 Jan; 42 Suppl 1():S40-8. PubMed ID: 26730973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
